The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): Analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial

Blood

Volumn 98, Issue 5, 2001, Pages 1312-1320

  Grimwade, David ^a,b,c,d,e,f   Walker, Helen ^a,b,c,d,e,f   Harrison, Georgina ^a,b,c,d,e,f   Oliver, Fiona ^a,b,c,d,e,f   Chatters, Stephen ^a,b,c,d,e,f   Harrison, Christine J ^a,b,c,d,e,f   Wheatley, Keith ^a,b,c,d,e,f   Burnett, Alan K ^a,b,c,d,e,f   Goldstone, Anthony H ^{a,b,c,d,e,f,g}  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d RADCLIFFE INFIRMARY   (United Kingdom)

^e ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^f UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^g UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER RISK; CLINICAL TRIAL; CYTOGENETICS; HUMAN; KARYOTYPE; MAJOR CLINICAL STUDY; MEDICAL RESEARCH; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME; UNITED KINGDOM;

EID: 0035469883     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V98.5.1312     Document Type: Article

References (40)

1. Hiddemann W, Kern W, Schoch C, et al. Management of acute myeloid leukemia in elderly patients. J Clin Oncol. 1999;17:3569-3576.
2. Goldstone AH, Burnett AK, Wheatley K, Smith AG, Hutchinson RM, Clark RE, on behalf of the Medical Research Council Adult Leukaemia Working Party. Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Blood. 2001;98:1302-1311.
3. Willman CL. Molecular evaluation of acute myeloid leukemias. Semin Hematol. 1999;36:390-400.
4. Dastugue N, Payen C, Lafage-Pochitaloff M, et al. Prognostic significance of karyotype in de novo adult myeloid leukemia. Leukemia. 1995;9:1491-1498.
5. Leith CP, Kopecky KJ, Godwin J, et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biological subgroups with remarkably distinct responses to standard chemotherapy: a Southwest Oncology Group study. Blood. 1997;89:3323-3329.
6. Mrózek K, Heinonen K, de la Chapelle A, Bloom-field CD. Clinical significance of cytogenetics of acute myeloid leukemia. Semin Oncol. 1997;24:17-31.
7. Mrózek K, Heinonen K, Bloomfield CD. Prognostic value of cytogenetic findings in adults with acute myeloid leukemia. Int J Hematol. 2000;72:261-271.
8. Grimwade D, Walker H, Oliver F, et al, on behalf of the Medical Research Council Adult and Children's Leukaemia Working Parties. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML10 trial. Blood. 1998;92:2322-2333.
9. Wheatley K, Burnett AK, Goldstone AH, et al. A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML10 trial. United Kingdom Medical Research Council's Adult and Childhood Leukaemia Working Parties. Br J Haematol. 1999;107:69-79.
10. Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study. Blood. 2000;96:4075-4083.
11. Burnett AK, Grimwade D, Solomon E, Wheatley K, Goldstone AH. Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-transretinoic acid: result of the randomized MRC trial. Blood. 1999;93:4131-4143.
12. Hann IM, Stevens RF, Goldstone AH, et al. Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia: results of the Medical Research Council's 10th AML trial (MRC AML10). Blood. 1997;89:2311-2318.
13. Cheson BD, Cassileth PA, Head DR, et al. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myelogenous leukemia. J Clin Oncol. 1990;8:813-819.
14. Harousseau JL. Acute myeloid leukemia in the elderly. Blood Rev. 1998;12:145-153.
15. Cahn JY, Labopin M, Mandelli F, et al. Autologous bone marrow transplantation for first remission acute myeloblastic leukemia in patients older than 50 years: a retrospective analysis of the European Bone Marrow Transplant Group. Blood. 1995;85:575-579.
16. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998;91:756-763.
17. Grimwade D. The pathogenesis of acute promyelocytic leukaemia: evaluation of the role of molecular diagnosis and monitoring in the management of the disease. Br J Haematol. 1999;106:591-613.
18. Fenaux P, Chastang C, Chevret S, et al. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. Blood. 1999;94:1192-1200.
19. Druker BJ, Lydon NB. Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest. 2000;105:3-7.
20. Redner RL, Wang J, Liu JM. Chromatin remodeling and leukemia: new therapeutic paradigms. Blood. 1999;94:417-428.
21. Warrell RP, He L-Z, Ricon V, Calleja E, Pandolfi PP. Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J Natl Cancer Inst. 1998;90:1621-1625.
22. Gajewski JL, Ho WG, Nimer SD, et al. Efficacy of intensive chemotherapy for acute myelogenous leukemia associated with a pre-leukemic syndrome. J Clin Oncol. 1989;7:1637-1645.
23. Leith CP, Kopecky KJ, Chen I-M, et al. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group study. Blood. 1999;94:1086-1099.
24. Pedersen-Bjergaard J, Pedersen M, Roulston D, Philip P. Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukemia. Blood. 1995;86:3542-3552.
25. Rowley JD. Molecular genetics in acute leukemia. Leukemia. 2000;14:513-517.
26. Zhu Y-M, Das-Gupta EP, Russell NH. Microsatellite instability and p53 mutations are associated with abnormal expression of the MSH2 gene in adult acute leukemia. Blood. 1999;94:733-740.
27. Ben-Yehuda D, Krichevsky S, Caspi O, et al. Microsatellite instability and p53 mutations in therapy-related leukemia suggest a mutator phenotype. Blood. 1996;88:4296-4303.
28. Paietta E, Andersen J, Racevskis J, et al. Significantly lower P-glycoprotein expression in acute promyelocytic leukemia than in other types of acute myeloid leukemia: immunological, molecular and functional analyses. Leukemia. 1994;8:968-973.
29. Drach D, Zhao S, Drach J, Andreeff M. Low incidence of MDR1 expression in acute promyelocytic leukaemia. Br J Haematol. 1995;90:369-374.
30. Legrand O. Simonin G, Beauchamp-Nicoud A, Zittoun R, Marie J-P. Simultaneous activity of MRP1 and Pgp is correlated with in vitro resistance to daunorubicin and with in vivo resistance in adult myeloid leukemia. Blood. 1999;94:1046-1056.
31. Del Poeta G, Venditti A, Maurillo L, et al. The amount of spontaneous apoptosis predicts outcome in acute myeloid leukemia (AML) [abstract]. Blood. 2000;96(suppl 1):543a.
32. Legrand O, Perrot J-Y, Baudard M, et al. The immunophenotype of 177 adults with acute myeloid leukemia: proposal of a prognostic score. Blood. 2000;96:870-877.
33. Jahns-Streubel G, Braess J, Schoch C, et al. Cytogenetic subgroups in acute myeloid leukemia differ in proliferative activity and response to GMCSF. Leukemia. 2001;15:377-384.
34. Ohler L, Berer A, Aletaha D, et al. Cytogenetic risk groups in acute myeloblastic leukaemia differ greatly in their semi-solid colony growth. Br J Haematol. 2001;113:120-125.
35. Ailles LE, Gerhard B, Kawagoe H, Hogge DE. Growth characteristics of acute myelogenous leukemia progenitors that initiate malignant hematopoiesis in nonobese diabetic/severe combined immunodeficient mice. Blood. 1999;94:1761-1772.
36. Grimwade D, Harrison G, Walker H, et al, on behalf of UK MRC Working Parties. Hierarchical cytogenetic classification is highly predictive of outcome in AML arising at all ages: analysis of 4225 cases entered in the UK MRC leukaemia trials [abstract]. Blood. 2000;96(suppl 1):825a.
37. Schoch C, Haferlach T, Haase D, et al. Patients with de novo acute myeloid leukaemia and complex karyotype aberrations show a poor prognosis despite intensive treatment: a study of 90 patients. Br J Haematol. 2001;112:116-126.
38. Kiyoi H, Naoe T, Nakano Y, et al. Prognostic implication of Flt3 and N-Ras gene mutations in acute myeloid leukemia. Blood. 1999;93:3074-3060.
39. Rombouts WJC, Blokland I, Löwenberg B, Ploemacher RE. Biological characteristics and prognosis of adult acute myeloid leukemia with internal tandem duplications in the Flt3 gene. Leukemia. 2000;14:675-683.
40. Stirewalt DL, Kopecky KJ, Meshinchi S, et al. FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. Blood. 2001;97:3589-3595.